- Spectral Medical Inc. (EDT) progresses on Tigris for the use of Polymyxin B Hemoperfusion (PMX) in treating endotoxemia and septic shock
- The Tigris trial goal is reducing the 28-day mortality in subjects
- PMX is used for the early application of a direct injection to remove endotoxins in the bloodstream
- The candidate drug’s effect on patient mortality data has exceeded Spectral’s expectations
- The company recently opened another trial enrollment site in Colorado Springs
- Spectral Medical Inc. (EDT) is up 2.94 per cent trading at $0.35 per share as of 11:04 a.m. EST
Spectral Medical (EDT) has reported progress on its clinical trial of Tigris for treating endotoxemia and septic shock.
The Tigris trial goal is reducing the 28-day mortality in subjects with septic shock using the PMX early application cartridge.
PMX is used for the early application of direct injection to remove endotoxins in the bloodstream. It is approved for therapeutic use in Japan and Europe, and has been used on more than 300,000 patients to date.
The candidate drug’s effect on patient mortality data has exceeded Spectral’s expectations.
Of the three patients enrolled over the past month, two were enrolled because of an FDA-approved protocol allowing for the use of sequential organ failure assessment (SOFA) scoring in the study.
Spectral is seeing more traffic for the screening and enrollment of new patients.
Chris Seto, CEO of Spectral, commented,
“We attribute the increased enrollment to a number of factors, including the implementation of our United States Federal Food and Drug Agency approved SOFA amendment and new sites coming online.”
The company recently opened enrollment at the UC Health Memorial Hospital in Colorado Springs. It is one of the highest enrolling sites in the previous Euphrates trial.
However, Spectral has not been immune to the effects of COVID-19 and has had its research disrupted this past year.
With COVID cases falling, Spectral expects an increase in enrollment in the coming weeks.
Spectral Medical Inc. (EDT) is up 2.94 per cent trading at $0.35 per share as of 11:04 a.m. EST.
